What is Aeovian Pharmaceuticals?
Headquartered in San Francisco, Aeovian Pharmaceuticals is a research-stage biopharmaceutical enterprise dedicated to the development of novel therapeutics. The company's core scientific focus lies in the modulation of the mTORC1 pathway, a critical biological mechanism implicated in various age-related and metabolic conditions. By targeting this specific pathway, Aeovian aims to address significant unmet medical needs, positioning itself as a specialized player in the precision medicine sector. The firm's commitment to rigorous scientific inquiry and therapeutic innovation has established it as a noteworthy entity within the broader life sciences ecosystem, attracting interest from both venture capital firms and strategic health foundations.
How much funding has Aeovian Pharmaceuticals raised?
Aeovian Pharmaceuticals has raised a total of $142M across 3 funding rounds:
Series A
$37M
Debt
$50M
Series B
$55M
Series A (2019): $37M with participation from Sofinnova Investments, Evotec SE, venBio Partners, and Apollo Health Ventures
Debt (2024): $50M led by Hevolution Foundation
Series B (2025): $55M supported by Foresite Capital, Luma Group, Sofinnova, and Wilson Sonsini
Key Investors in Aeovian Pharmaceuticals
Sofinnova Investments
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
venBio Partners
A life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.
Foresite Capital
A multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data.
What's next for Aeovian Pharmaceuticals?
With the successful closure of its latest funding round, Aeovian Pharmaceuticals is well-positioned to intensify its research and development efforts. The strategic allocation of these funds will likely prioritize the advancement of its lead therapeutic candidates, potentially moving them closer to clinical-stage trials. Furthermore, the company is expected to leverage its strong investor network to navigate complex regulatory landscapes and explore potential partnerships that could enhance its market reach. As the firm continues to refine its mTORC1-modulating platform, the focus will remain on achieving key data readouts that validate its scientific thesis and enhance long-term enterprise value in the global biopharma market.
See full Aeovian Pharmaceuticals company page
